NEOS Investment Management LLC Acquires New Holdings in Masimo Co. (NASDAQ:MASI)

NEOS Investment Management LLC bought a new stake in Masimo Co. (NASDAQ:MASIFree Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,989 shares of the medical equipment provider’s stock, valued at approximately $350,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MASI. NBC Securities Inc. purchased a new position in Masimo in the 3rd quarter valued at about $34,000. Massachusetts Financial Services Co. MA purchased a new position in Masimo in the 3rd quarter valued at about $132,699,000. Blueshift Asset Management LLC purchased a new position in Masimo in the 3rd quarter valued at about $287,000. Campbell & CO Investment Adviser LLC purchased a new position in Masimo in the 3rd quarter valued at about $1,953,000. Finally, Navellier & Associates Inc. purchased a new position in Masimo in the 3rd quarter valued at about $553,000. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Masimo

In other news, Director Craig B. Reynolds sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $136.17, for a total transaction of $5,446,800.00. Following the completion of the sale, the director now owns 7,406 shares of the company’s stock, valued at $1,008,475.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 9.70% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on MASI shares. Piper Sandler upgraded shares of Masimo from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $126.00 to $160.00 in a report on Monday. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Wednesday, May 8th. BTIG Research increased their price objective on shares of Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, March 25th. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Finally, Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and increased their price objective for the stock from $148.00 to $170.00 in a report on Monday, April 15th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Masimo currently has an average rating of “Moderate Buy” and a consensus target price of $143.57.

Read Our Latest Report on Masimo

Masimo Stock Down 4.2 %

MASI opened at $124.62 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.31 and a current ratio of 2.31. Masimo Co. has a 1 year low of $75.22 and a 1 year high of $169.58. The firm has a 50 day moving average price of $132.61 and a 200 day moving average price of $125.20. The company has a market cap of $6.62 billion, a PE ratio of 84.78 and a beta of 1.00.

Masimo (NASDAQ:MASIGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.06. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The company had revenue of $492.80 million during the quarter, compared to the consensus estimate of $487.70 million. During the same quarter last year, the company earned $0.87 earnings per share. Masimo’s revenue for the quarter was down 12.8% on a year-over-year basis. Sell-side analysts expect that Masimo Co. will post 3.63 earnings per share for the current year.

Masimo Company Profile

(Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Featured Articles

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.